Clinical Trials Data Bank Now Accessible
FDA Issues Guidance on Information Submission
ROCKVILLE, MD-The first public version of the Clinical Trials Data Bank can now be accessed at http://clinicaltrials.gov. The Modernization Act enacted in November 1997 directs the Secretary of Health and Human Services, acting through the Director, National Institutes of Health (NIH), to establish and maintain a data bank of information on clinical trials of new treatments for serious or life-threatening diseases and conditions. The data bank includes information about both federal and privately funded clinical trials, a description of the purpose of the experimental drug, patient eligibility criteria, location of the trial site, and a point of contact for individuals who want to participate. Section 113 of the Modernization Act stipulates the data bank information be in a format easily understood by the public.
Though this first phase of the data bank includes mostly NIH-sponsored trials, later in the year data from other Federal agencies and private companies should be included. In conjunction with the release of the database, the Food and Drug Administration (FDA) created a guidance document for sponsors of investigational new drug applications to submit information to the data bank. The guidance only proposes the statutory requirements for submission of information, not an actual implementation plan addressing procedural issues. The guidelines for submission include data, time, and certification requirements. There are guidelines for providing additional information.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
